tradingkey.logo

Sol Gel Technologies Ltd

SLGL
41.580USD
-0.580-1.38%
交易中 美東報價延遲15分鐘
115.83M總市值
虧損本益比TTM

Sol Gel Technologies Ltd

41.580
-0.580-1.38%

關於 Sol Gel Technologies Ltd 公司

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd簡介

公司代碼SLGL
公司名稱Sol Gel Technologies Ltd
上市日期Feb 01, 2018
CEO- -
員工數量34
證券類型Ordinary Share
年結日Feb 01
公司地址Golda Meir 7
城市NESS-ZIONA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編- -
電話97289313433
網址http://www.sol-gel.com
公司代碼SLGL
上市日期Feb 01, 2018
CEO- -

Sol Gel Technologies Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.77%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
其他
3.99%
持股股東
持股股東
佔比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.77%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
其他
3.99%
股東類型
持股股東
佔比
Corporation
64.86%
Hedge Fund
13.77%
Investment Advisor
7.86%
Individual Investor
5.14%
Insurance Company
4.68%
Research Firm
0.16%
其他
3.53%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
139.39K
5%
+139.39K
--
Aug 22, 2025
Phoenix Investment and Finances Ltd
247.02K
8.87%
+1.00
+0.00%
Jun 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Migdal Insurance and Financial Holdings Ltd
122.75K
4.41%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
5.33K
0.19%
-3.90K
-42.24%
Jun 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
-200.00
-38.76%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
308.00
0.01%
-1.00
-0.32%
Jun 30, 2025
SBI Securities Co., Ltd.
100.00
0%
--
--
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
May 01, 2025
Merger
10→1
公告日期
類型
比率
May 01, 2025
Merger
10→1

常見問題

Sol Gel Technologies Ltd的前五大股東是誰?

Sol Gel Technologies Ltd的前五大股東如下:
M.Arkin Dermatology, Ltd.
持有股份:1.81M
佔總股份比例:64.86%。
Opaleye Management Inc.
持有股份:139.39K
佔總股份比例:5.00%。
Phoenix Investment and Finances Ltd
持有股份:247.02K
佔總股份比例:8.87%。
Arkin (Moshe)
持有股份:143.26K
佔總股份比例:5.14%。
Migdal Insurance and Financial Holdings Ltd
持有股份:122.75K
佔總股份比例:4.41%。

Sol Gel Technologies Ltd的前三大股東類型是什麼?

Sol Gel Technologies Ltd 的前三大股東類型分別是:
M.Arkin Dermatology, Ltd.
Opaleye Management Inc.
Phoenix Investment and Finances Ltd

有多少機構持有Sol Gel Technologies Ltd(SLGL)的股份?

截至2025Q3,共有35家機構持有Sol Gel Technologies Ltd的股份,合計持有的股份價值約為286.02K,占公司總股份的10.27% 。與2025Q2相比,機構持股有所增加,增幅為-79.61%。

哪個業務部門對Sol Gel Technologies Ltd的收入貢獻最大?

在--,--業務部門對Sol Gel Technologies Ltd的收入貢獻最大,創收--,占總收入的--% 。
KeyAI